Contact us Demo our platform

Metabolon @

ASHG 2025

Join Metabolon at ASHG 2025

Metabolon is excited to attend ASHG 2025 in Boston, MA. This event is the world’s largest human genetics meeting and exposition, providing a forum for the presentation and discussion of cutting-edge science in all areas of human genetics and genomics. Katherine Black, Ph.D., Tony Di Meco, Ph.D., Heino Heyman, Ph.D., Gordon Irvine, Ph.D., and Michael Schilling will be in the exhibition area. Come by booth # 1160 to learn how metabolomics redefines multiomic research and unlocks actionable insights into human genetics and the genotype-phenotype map.

We look forward to participating in collaborative sessions, scientific discussions, and networking events that will help shape the future of human genetics.

Key Themes at ASHG 2025

ASHG 2025 will bring together the brightest minds in the field for five days of cutting-edge science, groundbreaking discoveries, and unparalleled networking opportunities. Notable areas of focus include:

  • Advocacy
  • AI and Machine Learning Applications
  • Bioinformatics and Computational Methods
  • Cancer Genetics
  • Ethics and Community Engagement (Including Genetic Counseling)
  • Functional Genomics
  • Gene-based Therapies/Therapeutics
  • Genomic and Precision Medicine
  • Population Genomics
  • Rare Diseases
  • Statistical Genetics
  • Women’s and Reproductive Health

Metabolomics is an essential thread running through these themes, offering a powerful means of connecting genetics, health, and the environment. See more information on the ASHG 2025 Program

The Role of Metabolomics in Human Genetics

Metabolomics is a vital and dynamic adjunct to genetic research—revealing how genes truly translate into health (or disease) by reflecting ongoing biological processes. Whether identifying unknown genetic effects, uncovering biomarkers, guiding personalized medicine, or integrating environmental influences, metabolomics brings context, clarity, and actionable insights that genomics alone cannot provide.

Find out more:
· Why Metabolomics: Your Guide to Metabolomics – Metabolon

Metabolon Poster Sessions

Wednesday, October 15, 2025 
2:30 PM-4:30 PM 
Abstract Title: Metabolomic Insights into COPD: Causal Links from a Multi-Ethnic Cohort 

Thursday, October 16, 2025 
2:30 PM-4:30 PM  
Abstract Title: Characterizing Metabolic Signatures of Polycystic Ovary Syndrome to Better Define Clinical Phenotypes

Why Connect with Metabolon at ASHG 2025?

Why Metabolon

With 25 years of scientific expertise, over 4,000 publications, more than 15,000 completed projects, and the world’s largest curated metabolite reference library (with more than 5,400 level 1 and level 2 annotated metabolites), Metabolon is the global leader in metabolomics.

Built on high-resolution mass spectrometry and rigorous quality controls, our platform delivers accurate, quantitative metabolite data across species and matrices.

To maximize the value of metabolomic data, we provide an Integrated Bioinformatics Platform that brings together metabolomics with genomics, transcriptomics, and other omics data. Designed for collaboration and with advanced statistical tools, interactive visualizations, and machine learning capabilities, researchers can generate system-wide insights that support evidence-based livestock science and policy.

We’re looking forward to meaningful conversations at ASHG!

Don’t stay behind – incorporate high-quality metabolomics analysis in your project. Book a meeting with our experts by filling in the form on this page!

Meet Metabolon’s Team at ASHG

Katherine Black, Ph.D, – Business Development Executive

Katherine earned her Ph.D. in Biochemistry from Wake Forest University. She completed her postdoctoral training at Weill Cornell Medicine, where she applied metabolomics and biochemical approaches to characterize potential drug targets in tuberculosis. For the past 6 years, she has drawn on her scientific expertise to help researchers accelerate discoveries through metabolomics-based solutions.

Tony Di Meco, Ph.D,- Business Development Executive

Tony holds a Master’s in Pharmaceutical Biotechnologies from the University of Rome “La Sapienza” and a PhD in Biomedical Sciences from Temple University. He completed a postdoctoral fellowship at Northwestern University in Chicago, where he applied multiomic approaches (metagenomic, transcriptomic, and metabolomic) to dissect the effect of gut microbiome changes on brain astrocyte phenotype in Alzheimer’s Disease.

In his commercial career, Tony supported the drug discovery community in characterizing molecular interactions as part of the Bruker group.

At Metabolon, Tony supports the clinical, pharmaceutical, and academic community in gaining unprecedented insights for metabolomic and multiomic analysis.

Heino Heyman, Ph.D- Director, Global Field Metabolomics Sciences

Dr. Heino Heyman is a seasoned metabolomics pro with over a decade of hands-on experience bridging research and real-world applications. Grounded in his early work

establishing workflows for natural products and crop resilience in South Africa, plus expanding into diverse omics at PNNL and advancing ion-mobility mass spec at Bruker, he brings a well-rounded perspective to Metabolon. Since joining in 2020, he’s deepened translational science efforts, and as Global Metabolomics Application Lead since 2023, he leads a dynamic team elevating client experiences in pharma, population health, and beyond.

Gordon Irvine, Ph.D,- Strategic Account Manager- Pharma

Dr. Irvine received his Ph.D. in Chemistry from The University of Western Ontario, where he developed novel mass spectrometry approaches to better understand metalloprotein structure. Following this, he was a postdoctoral scientist at Nanyang Technological University and then at UT Dallas where he worked on lipidomic method development and uncovering fundamental mechanisms of metal transport across membranes under the guidance of Dr. Gabriele Meloni. Dr. Irvine has since been an accomplished contributor within the commercial division of Metabolon Inc. where he has facilitated research partnerships that leverage Metabolon’s metabolic profiling technology to gain fundamental insight into complex biological systems. He is passionate about educating scientists, clinicians, and engineers about the wide-ranging applications of metabolomics and how this technology can drive the development of accurate preclinical models, understanding of target biology, target ID/validation, and bioprocessing optimization.

Becky Wilson, Ph.D.- Population Health Business Development Executive

Dr. Becky Wilson is a PhD-trained biochemist with expertise in molecular physiology who leads Metabolon’s Population Health initiatives. Previously a Study Director in Discovery and Translational Sciences, she brings deep experience in biomarker discovery and translational research. Her current focus is on advancing large-scale cohort studies and multiomics initiatives.

Dr. Heino Heyman is a seasoned metabolomics pro with over a decade of hands-on experience bridging research and real-world applications. Grounded in his early work establishing workflows for natural products and crop resilience in South Africa, plus expanding into diverse omics at PNNL and advancing ion-mobility mass spec at Bruker, he brings a well-rounded perspective to Metabolon. Since joining in 2020, he’s deepened translational science efforts, and as Global Metabolomics Application Lead since 2023, he leads a dynamic team elevating client experiences in pharma, population health, and beyond.

Learn More About ASHG 2025

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.